Welcome to the second issue of the reformatted and quarterly Licensing Economics Review. This issue includes the 2015 Royalty Rate Annual Industry Summary. Our curators added 623 license deals to the calculations and we provide updated average rates by industry. We include quartile measures too.
Licensing deals across a variety of technologies are reviewed for the 4th quarter. These include IP for oral-insulin capsules, cell phone apps, automobile manufacturing, cancer treatments and Alzheimer disease treatments. Arthritis was the focus of three licenses and renal or kidney treatment IP in another three licenses.
Universities and nonprofit organizations were significant players in at least two of the deals. Vaccine-development technology from John Hopkins University and stem-cell related IP from Case Western Reserve University were at the heart of two licenses. Both were licensed into Japan. Japan was prominent in several licenses with Japan-based Astellas part of three licenses – irritable bowel treatments, renal cell cancer therapies and vaccine technology.
The creative arts are represented by two articles, both lawsuits. The former bass player in the rock band New Order is suing his band members for cutting him out of some royalties. A famous rapper is suing his music company for shorting him on royalties from collaboration and solo albums.
Litigation is also well represented with the Sturgis Rally trademark case, the Ericsson fight in India over core mobile phone technologies and the two creative arts cases mentioned above. The Erbitux scandal was in the news as Sam Waksal rises like a phoenix in his new company Kadmon.
The “View from My Desk” interview is with Uzi Aloush, CEO of SynPat. Uzi has a unique strategic perspective on patent monetization. He provides many nuggets as food for thought.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.